Lucitanib (E3810 or AL3810) is a reversible, ATP‐competitive TKI that targets FGFR1‐2 and VEGFR1‐3 in the nM range and exerts antitumour activity in multiple preclinical models, including colon, ovarian, renal and thyroid carcinoma and breast cancer.40, 163, 164. Here, FGFR1 is linked to breast carcinoma.